Investors & Media

What’s new.

Press releases

Press releases.

July 22nd 2024

Immutep Announces Successful Meeting with FDA on Phase III Design in Non-Small Cell Lung Cancer

July 17th 2024

Immutep Receives Regulatory Clearance for Phase I Study of First-in-Class LAG-3 Agonist Antibody Designed to Treat Autoimmune Diseases

July 12th 2024

Immutep Reports Positive Results in First Line Head and Neck Squamous Cell Carcinoma Patients with Negative PD-L1 Expression

more

Investor updates

Investor updates.

February 21st 2024

Investor Update - February 2024

August 18th 2023

Investor Update - August 2023

November 17th 2022

Investor Update - November 2022

more

Analyst reports

Analyst reports.

Wilsons - Next steps for Efti in HNSCC; Maintain Overweight, A$1.05 PT (Analysts: Dr Melissa Benson and Dr Shane Storey)

July 15th 2024

Bell Potter - TACTI-003 Cohort B Update; Maintain Buy, A$0.75 (Analyst: Thomas Wakim)

For a copy of this research report please contact your Bell Potter advisor

July 12th 2024

Canaccord Genuity - Efti continues to impress in CPS<1 HNSCC patients; Maintain Buy, A$0.95 PT (Analyst: Elyse Shapiro)

For a copy of this research report please contact your Canaccord Genuity advisor

more